Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA review date set for birth control device:

This article was originally published in Clinica

Executive Summary

Conceptus' minimally invasive device for permanent birth control is scheduled for review by US FDA advisors during the July 22-23 meeting of the agency's Obstetrics and Gynecology Devices Panel. This Essure device is delivered by a hysteroscopic procedure, without the need for an abdominal incision and, in most women, the placement procedure does not require general anaesthesia, says the San Carlos, California firm.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT066667

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel